

03 Dec 2021 | Analysis

# ASH Preview: Three Areas To Watch In Hematology-Oncology

by [Alaric DeArment](#)

Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.

The American Society of Hematology meeting is back for 2021, at least partially, taking place as a hybrid conference online and in person in Atlanta 11-14 December, with a variety of companies showcasing their latest clinical findings in hematological cancers and blood disorders.

Below is a selection of data appearing at this year's ASH meeting that have been generating buzz among analysts.

## Novartis Hopes To Play Catch-Up In CAR-T Race

CAR-T cell therapies have taken top billing at ASH for multiple years, as new entrants have expanded the still nascent market, with 2021 seeing the US Food and Drug Administration approval of [Bristol Myers Squibb Company](#) and [bluebird bio](#)'s BCMA-targeting Abecma (idecabtagene vicleucel) for multiple myeloma, BMS's CD19-targeting Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma (LBCL), and most recently a label expansion for [Gilead Sciences, Inc.](#)'s Tecartus (brexucabtagene autoleucel) for adult acute lymphoblastic leukemia (ALL), after its 2020 approval for mantle cell lymphoma (MCL). (Also see "[Gilead/Kite's Tecartus Moves Into Leukemia With Second US Indication](#)" - Scrip, 4 Oct, 2021.)

[Novartis AG](#) was the first company to win approval for a CAR-T therapy, the CD19-targeting Kymriah (tisagenlecleucel), for pediatric ALL in 2017 and diffuse large B-cell lymphoma (DLBCL) the following year. But since then, it has somewhat fallen behind in terms of output, while Gilead and BMS now boast multiple cell therapies under their belts. However, the Swiss drug maker is now looking to catch up and plans to present Phase I data on YTB323 in DLBCL. The company's main selling point for the new construct is its rapid manufacturing time, with less than two days required to manufacture the final product with the T-Charge manufacturing platform, which is

designed to improve cell persistence, driving higher response rates and longer durability of response.

Data from 15 patients across three dose levels from the YTB323 abstract showed that at dose level 1, the overall response rate (ORR) and complete response rate (CR) were both 25%, while at dose level 2 they were both 75%. In terms of adverse events (AE), four patients experienced at least one grade 3 AE, six experienced at least one grade 4 AE, and two experienced at least one fatal AE, however all four deaths on trial were deemed unrelated to the therapy. Cytokine-release syndrome (CRS) occurred in four patients – including three at grade 1-2 and one at grade 4, which met dose-limiting toxicity criteria. Seven patients experienced neurological AEs, including two considered serious, namely grade 3 peripheral neuropathy unrelated to therapy and grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) deemed related.

One company that has gotten a significant amount of attention is [Fate Therapeutics, Inc.](#), which is presenting data on the CD19-targeting CAR-NK therapy FT596, along with the induced pluripotent stem cell (iPSC)-derived NK cell therapy FT516 combined with anti-CD20 monoclonal antibody – either [Roche Holding AG](#)'s Rituxan (rituximab) or Gazyva (obinutuzumab) – in B-cell non-Hodgkin's lymphomas (NHL). The company previously presented data on FT516/Rituxan at the American Society of Clinical Oncology meeting in June, when it provided a promising sign of the therapy's efficacy in NHL and potential applicability beyond hematological cancers, albeit with the caveat that the data were early. (Also see "[Fate's Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed](#)" - Scrip, 9 Jun, 2021.)

According to the FT516 abstract, eight of 11 patients who received at least 90 million FT516 cells responded to treatment, including seven who achieved CRs, while five responders remained in remission at between 4.6-9.5 months. No dose-limiting toxicities, serious AEs or grade 3 or higher AEs related to FT516 were observed.

For FT596, of 17 efficacy-evaluable patients, five of eight in the monotherapy arm and four of nine in the CD20 antibody-combination arm responded. Eight of 11 patients that received at least 90 million cells responded, including seven CRs. Two patients with prior CAR-T treatment achieved CRs as well. No cases of graft-versus-host disease or ICANS were observed, while there were two cases of grade 1-2 CRS.

## **Bispecifics Move Ahead, With New Targets And Old**

Roche's anti-CD20 Rituxan has long been a mainstay in treatment of B-cell non-Hodgkin's lymphomas, forming the backbone of chemotherapy combinations like R-CHOP. But even with the availability of biosimilar versions such as [Celltrion, Inc.](#)'s Truxima and [Amgen, Inc.](#)'s Riabni, multiple companies have been developing bispecific antibodies that target CD20 on cancerous B-cells and CD3 on T-cells.

This year's ASCO meeting showcased multiple anti-CD20 bispecific antibodies, including Roche's glofitamab and mosunetuzumab and [Genmab A/S/AbbVie Inc.](#)'s epcoritamab. But while they showed strong efficacy, Rituxan and its biosimilars remain sufficiently entrenched in the NHL treatment armamentarium that it may prove difficult to dethrone, with the bispecific antibodies seeming likely to play more of a niche role. (Also see "[Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma](#)" - Scrip, 8 Jun, 2021.)

Initial results from a Phase I/II study of subcutaneous mosunetuzumab at ASH show that in 38 efficacy-evaluable patients with FL and DLBCL, 19 responded to treatment. CRS occurred in 24.3% of patients, though none at grade 3 or higher.

Another study with preliminary data is a Phase Ib/II trial of glofitamab with Roche's CD79b-targeting antibody-drug conjugate, Polivy (polatuzumab vedotin-piiq) in DLBCL. At cutoff, 33 of 44 patients were evaluable for efficacy, and the ORR was 73%, while the CR rate was 51.5%. Of 42 patients, CRS occurred in 55%, though not at grade 3 or higher.

Preliminary results of a Phase I/II study combining epcoritamab with Rituxan and BMS's Revlimid (lenalidomide) in 16 patients showed that all five efficacy-evaluable patients responded, including four CRs. CRS occurred in 31% of patients, but all at grade 1-2.

Another CD20xCD3-targeting bispecific drug is [Xencor, Inc.](#)'s XmAb13676 (plamotamab). Updated data from 80 patients in a Phase I study showed that among those who were efficacy-evaluable, the ORR was 43.4%, which Mizuho analyst Mara Goldstein said in a 17 November note was a "modest improvement" over a 38.9% ORR at ASH 2019. (Also see "[Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience](#)" - Scrip, 19 Dec, 2019.) However, among eight patients who received flat dosing instead of weight-based dosing, the ORR was 50%. Overall, 62.5% of patients experienced CRS, with 5% experiencing it at grade 3 or higher.

Beyond NHL, multiple myeloma is also the subject of bispecific antibody studies appearing at ASH. These include Genmab/[Johnson & Johnson](#)'s talquetamab, a GPRC5DxCD3-targeting bispecific antibody, for which the companies will present updated Phase I data and first-time combination therapy results with the company's CD38 inhibitor Darzalex (daratumumab). J&J's BCMAxCD3 bispecific teclistamab also will have updated Phase I and early Darzalex combination data at ASH. Roche plans to present Phase I data on cevostamab, which targets FcRH5xCD3.

In the talquetamab monotherapy study, the ORR was 70% among 30 efficacy-evaluable patients, with 57% achieving a very good partial response (VGPR) or better. CRS occurred in 70% of 30 patients who received the recommended Phase II dose of 405mcg/kg weekly.

For cevostamab, among 158 efficacy-evaluable patients, the ORR was 54.5% among 44 patients receiving the 160mg dose and 36.7% among those receiving the 90mg dose. Among the total 160

patients, grade 1, grade 2 and grade 3 CRS occurred in 42.5%, 36.3% and 1.3% of patients, respectively. ICANS associated with CRS occurred in 13.1% of patients.

## PI3K Market Heats Up As Next-Generation BTKs Move Ahead

When it comes to small molecules, some of the biggest highlights at ASH are drugs designed to improve upon two classes of kinase inhibitors for blood cancers, namely PI3K and BTK inhibitors.

[\*Incyte Corporation\*](#) plans to present Phase II data on piasclisib, its PI3K-delta inhibitor, in relapsed/refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL) from the CITADEL-203 and CITADEL-204 studies, respectively, as well as from the CITADEL-205 study in MCL. The FDA is expected to decide whether to approve the drug in FL and MCL by 30 April 2022 and in MZL by 30 August 2022.

But although piasclisib belongs to a new generation of PI3K-delta inhibitors designed to address the safety issues that have long dogged the class, the market may soon find itself dominated by [\*MEI Pharma, Inc.\*](#) and [\*Kyowa Kirin Co., Ltd.\*](#)'s zandelisib. The companies announced Phase II data in relapsed and refractory FL on 30 November showing both a high response rate – including a complete response rate uncommon among the class – but with apparently lower toxicity even than other PI3K-delta inhibitors designed to overcome that limitation. (Also see "[Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?](#)" - Scrip, 30 Nov, 2021.)

According to the CITADEL studies, piasclisib administered daily or weekly produced ORR and CR rates of 75.4% and 18.3% in FL (n=126); 58% and 6% in MZL (n=100); and 68.5% and 17.6% in MCL (n=108). Rates of fatal treatment-emergent AEs (TEAE) were 1.6% in CITADEL-203, 6% in CITADEL-204 and 5.6% in CITADEL-205. Two patients in CITADEL-204 experienced fatal AEs – febrile neutropenia and sepsis – considered treatment-related.

Generally speaking, BTK inhibitors have not had the same problems as their PI3K counterparts, but some patients are nevertheless resistant to them or relapse after receiving them, particularly covalent BTK inhibitors like AbbVie/J&J's Imbruvica (ibrutinib), [\*AstraZeneca PLC\*](#)'s Calquence (acalabrutinib) and [\*BeiGene, Ltd.\*](#)'s Brukinsa (zanubrutinib). This is mainly due to C481S mutations. [\*Merck & Co., Inc.\*](#) plans to present Phase II data on MK-1026 – formerly ARQ 531 – a non-covalent BTK inhibitor, in patients with various hematological malignancies. Merck acquired the drug's developer, ArQule, in December 2019, for \$2.7bn. (Also see "[Merck & Co. Joins Competitive BTK Research Space With \\$2.7bn ArQule Buy](#)" - Scrip, 9 Dec, 2019.)

Data from Merck's presentation show that among 38 efficacy-evaluable patients with CLL/SLL, the ORR was 57.9%, or 22 responses, including one CR. Among 118 treated patients, 97% experienced a TEAE, with 8% having one that led to discontinuation, and 68% experiencing grade 3 or higher AEs. Seven experienced fatal AEs, but none were drug related.

*Eli Lilly and Company's* Loxo Oncology at Lilly plans to present updated data from the Phase I/II BRUIN trial of pirtobrutinib (LOXO-305). The presentation follows data that the division presented at ASH 2020. (Also see "*Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL*" - Scrip, 7 Dec, 2020.)

Among 323 patients enrolled in BRUIN as of September 2020, 139 with CLL/SLL were efficacy-evaluable. The ORR was 63%, with 50% experiencing PRs, 14% experiencing PR with lymphocytosis (PR-L) and 32% experiencing stable disease. The ORR was 62% among patients previously treated with a BTK inhibitor.